Paper39748842
The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.
Bakker A and 3 others. Alzheimers Dement (N Y), 2024. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease. Papers, record 39748842. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39748842
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 AG066507 | NIA NIH HHS | United States | P30AG066507 | PubMed | NIH RePORTER |
| R01 AG048349 | NIA NIH HHS | United States | R01AG048349 | PubMed | NIH RePORTER |
| R01 AG061091 | NIA NIH HHS | United States | R01AG061091 | PubMed | NIH RePORTER |
| R56 AG055416 | NIA NIH HHS | United States | R56AG055416 | PubMed | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 40642320 | Correction to "The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease". | https://conductscience.org/library/papers/40642320 |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25181316 | Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment. | Hum Brain Mapp | 2015 | https://conductscience.org/library/papers/25181316 | PubMed |
| 2 | 38356475 | The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD. | Alzheimers Dement (N Y) | 2024 | https://conductscience.org/library/papers/38356475 | PubMed |
| 3 | 22869752 | Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22869752 | PubMed |
| 4 | 20032967 | Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. | Neuropsychopharmacology | 2010 | https://conductscience.org/library/papers/20032967 | PubMed |
| 5 | 36251300 | Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. | JAMA Neurol | 2022 | https://conductscience.org/library/papers/36251300 | PubMed |
| 6 | 30552075 | Cortical thickness atrophy in the transentorhinal cortex in mild cognitive impairment. | Neuroimage Clin | 2019 | https://conductscience.org/library/papers/30552075 | PubMed |
| 7 | 13677801 | Neuroimaging in Alzheimer disease: an evidence-based review. | Neuroimaging Clin N Am | 2003 | https://conductscience.org/library/papers/13677801 | PubMed |
| 8 | 39748842 | The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease. | Alzheimers Dement (N Y) | 2024 | https://conductscience.org/library/papers/39748842 | PubMed |
| 9 | 22578498 | Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. | Neuron | 2012 | https://conductscience.org/library/papers/22578498 | PubMed |
| 10 | 16087905 | Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. | Neurology | 2005 | https://conductscience.org/library/papers/16087905 | PubMed |
| 11 | 28269019 | ITK-SNAP: An interactive tool for semi-automatic segmentation of multi-modality biomedical images. | Annu Int Conf IEEE Eng Med Biol Soc | 2016 | https://conductscience.org/library/papers/28269019 | PubMed |
| 12 | 22732662 | Multi-Atlas Segmentation with Joint Label Fusion. | IEEE Trans Pattern Anal Mach Intell | 2013 | https://conductscience.org/library/papers/22732662 | PubMed |
| 13 | 10762153 | Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. | Ann Neurol | 2000 | https://conductscience.org/library/papers/10762153 | PubMed |
| 14 | 28971142 | Entorhinal and transentorhinal atrophy in mild cognitive impairment using longitudinal diffeomorphometry. | Alzheimers Dement (Amst) | 2017 | https://conductscience.org/library/papers/28971142 | PubMed |
| 15 | 10023955 | MRI of entorhinal cortex in mild Alzheimer's disease. | Lancet | 1999 | https://conductscience.org/library/papers/10023955 | PubMed |
| 16 | 21696834 | Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. | Trends Neurosci | 2011 | https://conductscience.org/library/papers/21696834 | PubMed |
| 17 | 33720637 | Donanemab in Early Alzheimer's Disease. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33720637 | PubMed |
| 18 | 21514249 | The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. | Alzheimers Dement | 2011 | https://conductscience.org/library/papers/21514249 | PubMed |
| 19 | 7566337 | Staging of Alzheimer's disease-related neurofibrillary changes. | Neurobiol Aging | 1995 | https://conductscience.org/library/papers/7566337 | PubMed |
| 20 | 20566298 | Non-local MRI upsampling. | Med Image Anal | 2010 | https://conductscience.org/library/papers/20566298 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42890321 | Comparative efficacy of non-pharmacological interventions for amnestic mild cognitive impairment: a network meta-analysis. | Front Aging Neurosci | 2026 | https://conductscience.org/library/papers/42890321 | PubMed |
| 42564239 | The impact of long-term antiseizure treatment on cognitive decline in late-onset epileptic prodromal Alzheimer's disease: an exploratory study. | Front Aging Neurosci | 2026 | https://conductscience.org/library/papers/42564239 | PubMed |
| 42453713 | Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment. | AIMS Neurosci | 2026 | https://conductscience.org/library/papers/42453713 | PubMed |
| 42344858 | Introducing the SAGE study: a multimodal protocol for testing a GABAergic mechanism of age-related episodic memory impairment across the sexes. | BMJ Neurol Open | 2026 | https://conductscience.org/library/papers/42344858 | PubMed |
| 42337959 | Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non-pharmacological strategies. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42337959 | PubMed |
| 41840186 | Maintaining and regaining episodic memory in Alzheimer disease: a circuit-based perspective. | Nat Rev Neurol | 2026 | https://conductscience.org/library/papers/41840186 | PubMed |
| 41599368 | Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer's Disease. | Molecules | 2026 | https://conductscience.org/library/papers/41599368 | PubMed |
| 41554957 | Excitation-inhibition homeostasis in Alzheimer's disease: a selective multiscale review of mechanisms, sex differences, and therapeutic opportunities. | Neuropsychopharmacology | 2026 | https://conductscience.org/library/papers/41554957 | PubMed |
| 40993829 | Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer's disease: associations with Aβ, tau, synaptic proteins and APOE ε4. | Transl Neurodegener | 2025 | https://conductscience.org/library/papers/40993829 | PubMed |
| 40608289 | Effect of levetiracetam on cognition in patients with cognitive decline: A systematic review and meta-analysis of randomized controlled trials. | Epilepsia Open | 2025 | https://conductscience.org/library/papers/40608289 | PubMed |
| 40595720 | Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease. | Nat Commun | 2025 | https://conductscience.org/library/papers/40595720 | PubMed |
| 39748842 | The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease. | Alzheimers Dement (N Y) | 2024 | https://conductscience.org/library/papers/39748842 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39748842
GET https://conductscience.org/api/papers/v1/39748842/references?page=2